ORGO News and Press, Organogenesis Holdings Inc. From 03/02/23

Organogenesis Holdings ( NASDAQ: ORGO ) has reported favorable outcome of the interim analysis of its Phase 3 trial of ReNu, a cryopreserved amniotic suspension allograft (ASA) for management of symptoms associated with knee osteoarthritis. The pre-specified interim analysis on 50...

Organogenesis Holdings Inc. (ORGO) Q4 2022 Earnings Conference Call March 1, 2023 17:00 ET Company Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG ...

Image source: The Motley Fool. Organogenesis (NASDAQ: ORGO) Q4 2022 Earnings Call Mar 01, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Organogenesis (ORGO) Q4 2022 Earnings Call Transcript

Organogenesis Holdings press release ( NASDAQ: ORGO ): Q4 GAAP EPS of $0.06. Revenue of $115.5M (-9.7% Y/Y). Sees FY 2023 net revenue between $450.0 million and $462.0 million. For further details see: Organogenesis Holdings reports Q4 results, introduces FY 2023 rev...

CANTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today r...

CANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today re...

Summary Aswath Damodaran is an investing and finance authority on markets & valuation, among many other things. In a 2022 interview, he provided a masterclass in inflation, some lessons in history, and potential ways to protect your portfolio this time around. In a previous piec...

CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, toda...

Summary Seeking Alpha's quant ratings system provides a valuable tool for analysis of thousands of stocks. Underlying metrics for momentum and revisions undercut Organogenesis' strong Quant valuation and profitability metrics. Quant ratings alone need supplementation; the stories un...

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...